Sarepta Therapeutics
SRPT
340 hedge funds and large institutions have $5.52B invested in Sarepta Therapeutics in 2019 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 128 increasing their positions, 101 reducing their positions, and 95 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 101
2.67% more ownership
Funds ownership: 96.59% → 99.26% (+2.7%)
4% less call options, than puts
Call options by funds: $232M | Put options by funds: $241M
7% less funds holding
Funds holding: 365 → 340 (-25)
23% less first-time investments, than exits
New positions opened: 73 | Existing positions closed: 95
38% less funds holding in top 10
Funds holding in top 10: 13 → 8 (-5)
49% less capital invested
Capital invested by funds: $10.9B → $5.52B (-$5.35B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$98.3M |
| 2 |
CCM
Cadian Capital Management
New York
|
+$83.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$82.3M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$75.7M |
| 5 |
BlackRock
New York
|
+$68.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
-$191M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$134M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$83.1M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$76M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$62.6M |
SRPT Hedge Fund Activity: Q3 2019 in Review
340 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2019, worth a combined $5.52B — down 49% from $10.9B a quarter earlier.
Sellers outnumbered buyers: 95 funds closed out of SRPT and 73 opened new positions — a net loss of 22 holders — while 101 trimmed existing stakes and 128 added.
The largest buyer was State Street, adding an estimated $98.3M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $191M sold.
- 340 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2019, down from 365 in Q2 2019.
- Funds reported $5.52B of Sarepta Therapeutics stock for Q3 2019, down 49% quarter-over-quarter.
- 73 funds opened new Sarepta Therapeutics positions in Q3 2019 and 95 closed out, a net change of -22 holders.
- The largest Sarepta Therapeutics buyer in Q3 2019 was State Street, an estimated $98.3M added.
- The largest Sarepta Therapeutics seller in Q3 2019 was TimesSquare Capital Management, an estimated $191M sold.
Based on aggregated 13F filings for Q3 2019.